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TaiwanA B S T R A C TObjective: To provide an overview of the use of biologics in Taiwan,
including the access to new biologics, the impact of this access on the
growth of health-care expenditure, and the utilization patterns.
Methods: Wefirst conducted amarket-level analysis to investigate the
availability of global biologics in Taiwan as well as the growth and
concentration of aggregate spending on biologics.We then conducted a
patient-level analysis to investigate the costs and utilization patterns
for selected new biologics. Results: We found that the concentration
index is such that the 20 leading biologics in Taiwan account for more
than 90% of the total spending on biologics. In our patient-level study
on four biologics, the annual cost of treatment per patient ranged from
NT$100,000 to NT$400,000. The prevalence rate of the user was be-
tween 6.5 and 37.2 per 100,000 of population. The treatment costs were
inversely related to the prevalence rate of users. We also found that
physicians in larger and public hospitals were more likely to prescribe
e no
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mics
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doi:10.1016/j.jval.2011.11.025new biologics to their patients compared with their counterparts prac-
ticing in smaller and private hospitals. In addition, we found that phy-
sicians were more likely to prescribe biologics to patients with more
severe diseases and higher comorbidities. Conclusions: We conclude
that public spending on biologics in Taiwan is highly targeted toward
about 20 products with higher annual expenditures and growth rates
and that the utilization of these biologics is targeted at a small number
of patients. In addition, the access to these costly biologics is not uni-
form among patients in a country with universal coverage for prescrip-
tion drugs.
Keywords: access to newbiologics, biologics, health-care costs, technol-
ogy diffusion.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Biologics are defined as medicines whose active substance is made
from a living organism or its products and are produced by using
biotechnology methods or other cutting-edge technologies. Bio-
logics differ from chemically synthesized drugs along many di-
mensions, including manufacturing, the market dynamics, mode
of administration, target specificity, body distribution, and half-
life [1–3]. In recent years, nearly one-fourth of all new chemical
entities launched in the United States and the European Union
have been biologics [4]. Thus, biologics are important new health-
care technologies. The market for biologics has grown more rap-
idly than that for general pharmaceutical products, and as a result
the share of biologics in global pharmaceutical sales has increased
rapidly from 4.4% in 1998 to 10.5% in 2007.
As observed in many other new technologies in medicine, the
adoption of biologics is costly. Compared with chemically synthe-
sized drugs, manufacturing biologics is much more complex.
Moreover, biologics have, until recently, usually targeted small
patient populations. Given these characteristics of their manufac-
turing and marketing, it is not surprising that the prices of many
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Published by Elsevier Inc.biologics are relatively high [5]. The high cost of adopting new
biologics often becomes a public concern, particularly in health
systems dominated by public financing where decisions about
which biologics will be covered by public programs can become
highly politicized. As a result, countries often face a policy di-
lemma between providing access to new biologics and controlling
their health-care budgets.
The purpose of this article was to provide an overview of the
use of biologics in Taiwan with a special focus on the accessibility
and cost impacts of new biologics. On the basis of both population
and sampling claims data obtained from the national health in-
surance (NHI) program, we performed market- and patient-level
analysis to explore several issues surrounding the utilization of
biologics in Taiwan. Specifically, we analyzed the access issue by
comparing the lists of biologics in Taiwan’s NHI formulary with
the list of blockbuster biologics in the global market. In addition,
we analyzed the trend of NHI spending on biologics over time.
Furthermore, we performed patient-level analysis for individual
biologics to analyze the costs and utilization patterns of selected
new biologics.
There are several advantages in using Taiwanese data to quan-
tify the impact of adopting new biologics on health-care costs and
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S36 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2utilization patterns. First, Taiwan has a social insurance system
providing universal insurance coverage for physician services,
hospital care, and prescription drugs. To control the cost of public
insurance, the government in Taiwan regulates the price paid by
the single health insurance plan for individual drugs [6]. The sin-
gle-payer system allows policymakers as well as researchers to
trace the impact of introducing new drugs on national health
costs.
Second, about one-quarter of Taiwan’s health-care expendi-
ture is on pharmaceuticals. As compared with other developed
countries, the higher spending makes it more likely for pre-
scription drugs to become the target of cost containment. As a
result, the experience of Taiwan provides a valuable insight into
understanding how policymakers struggle with the conflict be-
tween increasing access to new drugs and controlling health-
care costs.
Data and Methods
The data used in this study had two main sources. First, we ob-
tained data on the aggregate expenditure on biologics from NHI
population claims data. Second, we used a longitudinal data set to
analyze the costs and utilization patterns of individual biologics.
This data set contains 1 million individuals (about 4.35% of the
total population in Taiwan) randomly selected from the registry of
NHI beneficiaries in the year 2005. The sampling file was then
merged with the insurance claim files that trace back all the med-
ical utilization records of the same individuals in every year and
follow their medical utilizations in subsequent years, hereafter
referred to as the 2005 Longitudinal Health Insurance Database
(LHID).
The 2005 LHID was made publicly available through the Na-
tional Health Research Institute. This data set contains detailed
records on the utilization of personal health-care services, includ-
ing outpatient visits, hospital admissions, and prescription drugs.
Table 1 – Launch dates of blockbuster biologics in Taiwan.
Name of drug Manufacturin
Aranesp (darbepoetin alfa) Amgen
Avastin (bevacizumab) Genentech
Avonex (interferon beta-la) Biogen/IDEC
Betaseron (interferon beta-1b) Bayer Scherin
Cerezyme (imiglucerase) Genzyme
Enbrel (etanercept) Amgen
Erbitux (cetuximab) ImClone Syst
Herceptin (trastuzumab) Genentech
Humalog (insulin lispro injection) Eli Lilly
Humira (adalimumab) Abbott Labor
Lantus (insulin glargine injection) Sanofi-Avent
Neulasta (pegfilgrastim) Amgen
Neupogen (filgrastim) Amgen
Novolog (insulin aspart injection) Novo Nordisk
NovoSeven (coagulation factor VIIa) Novo Nordisk
Pegasys (peginterferon alfa-2a) Roche
Rebif (interferon beta-1a) MerckSerono
Remicade (infliximab) Centacor (J&J
Rituxan (rituximab) Genentech
Synagis (palivizumab) MedImmune
Note: Blockbuster biologics indicate that their annual sales exceeded
ATC, Anatomical Therapeutic Chemical classification system; NA, noWe merged the data for outpatient visits with the correspondingdrugs prescribed and dispensed by using anonymous identifica-
tion numbers. The advantage of this data set is that all themedical
utilizations can be linked together for the same patient. As a re-
sult, the data provide information on the characteristics of pa-
tients, providers, and the drugs prescribed.
In this article, we adopted two approaches to analyze the use of
biologics in Taiwan. We first conducted a market-level analysis to
investigate the availability of global biologics in Taiwan as well as
the growth and concentration of aggregate spending on biologics.
The advantage of this approach is that it provides population-
based information on the overall utilization of biologics in Taiwan.
Themarket-level analysis, however, does not provide information
on individual patients.We then conducted a patient-level analysis
to provide a descriptive analysis of the costs and utilization pat-
terns for four important biologics, namely, Enbrel, Mabthera, Her-
ceptin, and Pegasys, which were selected on the basis of higher
annual sales andhigher growth rates. In the patient-level analysis,
we analyzed the mean cost of treatment per patient by using the
cohort data that all the prescriptions have been linked together for
the same patients. By means of aggregation and four case studies,
we summarize the findings of this research.
Market-Level Analysis
Taiwan has established, under its system of NHI, a national for-
mulary that includes all pharmaceuticals subject to reimburse-
ment by the NHI. The detailed list of drugs in the drug formulary
provides a base on which to analyze the availability of biologics in
Taiwan by comparing the list based on the NHI formulary with the
list of important biologics in the global market.
In Table 1, we summarize a list of 20 important biologics in the
global market whose annual sales exceeded US$1 billion in 2007.
Among them, 14 biologics are available in Taiwan through the
coverage of public insurance. The launch dates of these biologics
range from 1998 to 2007. By 2007, six biologics—Avastin, Avonex,
ms ATC code Launch date
B03XA02 May 1, 2004
L01XC07 NA
– NA
L03AB08 March 1, 1998
A16AB02 October 22, 1998
L04AB01 March 1, 2003
L01XC06 March 1, 2007
L01XC03 April 1, 2002
A10AD04
February 1, 2004A10AB04
A10AC04
s L04AB04 September 1, 2004
A10AE04 February 1, 2004
L03AA13 NA
L03AA02 1995
A10AB05
2003
A10AD05
– NA
L03AB11 November 1, 2003
L03AB07 April 1, 2002
L04AB02 NA
L01XC02 April 1, 2002
J06BB16 NA
billion in 2007.
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S37V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2by public insurance. This result suggests that the probability of
new biologics being launched in Taiwan is 0.7. That is, for every 10
important biologics (in terms of sales) available in the global mar-
ket, only 7 biologics will be launched in the Taiwan market. A
plausible explanation for new drugs not being launched is a lower
expected price [7].
In the globalmarket,manynewbiologics have been introduced
annually as a consequence of technological advances [8]. In addi-
tion to requiring that authorization be obtained to market a new
biologic product, Taiwan, like other countries with direct price
controls on pharmaceutical products, requires that the manufac-
turer of a new biologic product obtain approval for insurance cov-
erage and a price for reimbursement by the single public payer. As
a result, many new biologics as well as other chemically synthe-
sized drugs are added to the NHI formulary annually. During the
period from 1997 to 2006, the annual number of new biologics
included in the NHI formulary varied year by year, ranging from 1
to 11, with the exception of the year 2000 in that no new biologic
product was launched in that year.
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Fig. 1 – Accumulated numbers of new biologics in the NHI
formulary and share of pharmaceutical spending on new
biologics. From Bureau of National Health Insurance,
Taipei, Taiwan. Note: New biologics are defined as those
included in the NHI formulary after 1997. NHI, national
health insurance.
Table 2 – NHI spending on biologics, pharmaceuticals, and
Year Total
health-care
expenditure
(billion NT$)
Total
pharmaceutica
expenditure
(billion NT$)
1998 290.9 73.0
1999 316.6 81.3
2000 326.0 84.1
2001 341.7 85.1
2002 370.9 92.2
2003 383.9 96.3
2004 438.8 111.1
2005 452.4 113.9
2006 456.4 116.4
Mean annual growth rate
between 1998 and
2006 (%)
5.8 6.0
Source: Bureau of National Health Insurance, Taipei, Taiwan; calcula
Note:
1. The average exchange rate was around 1 US$ to 32.5 NT$ in 1998–
2. Total pharmaceutical expenditure includes the expenditure on kid
NHI, national health insurance.Figure 1 shows the accumulated numbers of new biologics
added to the NHI formulary over time. A new biologic product is
defined here as one that was included in the formulary after 1997.
By 2006, the total accumulated number of new biologics included
in the NHI formulary was 45, indicating that on average about 4.5
new biologics were added to the NHI formulary annually. While
the total number of biologics accounts for only about 0.3% (68 of
21,000) of the total number of products listed in theNHI formulary,
as more new biologics have been included in the NHI formulary,
the share of NHI pharmaceutical expenditure accounted for by the
biologics has increased steadily, from 3.7% in 1998 to 6.8% in 2006.
This suggests that the introduction of new biologics into the for-
mulary is an important determinant of increased spending on pre-
scription drugs.
Although the market share of biologics in Taiwan has in-
creased over time, this share is lower than the mean share in the
global market. In 2005, the United States had the highest biologic
share (12.9%) in the world, with shares ranging between 8% and
10% amongmajor European countries [8]. By contrast, Japan had a
relatively low share of biologics in its total drug spending, that is,
only 5.4%. This suggests that the current utilization rates of bio-
logics in Taiwan are very lowas comparedwith those in theUnited
States and European countries, but are slightly higher than those
in Japan.
In spite of the lower market share, the spending on biologics
has grown more rapidly than the spending on general pharma-
ceutical products and health care. As shown in Table 2, the total
NHI health-care expenditure increased from NT$291 billion in
1998 to NT$456 billion in 2006 (USD 1  32.5 NTD, 1997–2006),
ndicating that the mean annual growth rate during this period
as 5.8%. As mentioned earlier, in Taiwan about one-quarter of
he expenditure of the NHI program was accounted for by phar-
aceuticals. Thus, the mean annual growth rate of pharmaceu-
ical expenditure was almost the same as that of health-care
xpenditure. By contrast, the mean annual growth rate of bio-
ogics was 14.4% between 1998 and 2006, which was more than
ouble the mean growth rate of pharmaceutical products and
eneral health care (Table 2). This suggests that biologics are
xpected to account for a much more significant share of the
ealth-care cost in the future.
lth care in Taiwan, 1998–2006.
Total
spending on
biologics
(billion NT$)
Share of drug
spending in total
NHI spending (%)
Share of biologics
spending in total
drug spending (%)
2.7 25.1 3.7
3.2 25.7 3.9
4.0 25.8 4.8
4.2 24.9 4.9
4.8 24.9 5.2
5.3 25.1 5.5
6.4 25.3 5.8
7.1 25.2 6.2
7.9 25.5 6.8
14.4 0.2 7.9
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S38 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2Table 3 shows the concentration index in terms of spending on
biologics. By 2006, the NHI formulary included 68 biologics. The
aggregate spending on biologics, however, has been highly con-
centrated among a few selected biologics. The best-selling biologic
product, erythropoietin, accounts for nearly one-quarter of spend-
ing on all biologics. The concentration index among the top four
biologics (in terms of sales) is more than 50%. The concentration
index among the 10 leading biologics in Taiwan is about 75%. The
20 leading biologics account for more than 90% of the total spend-
ing on biologics in Taiwan. The annual sales of these 20 biologics
range from NT$80 million to NT$1.8 billion. This result suggests
that spending on biologics in Taiwan is highly targeted at specific
therapeutic classes, such as insulins and analogues, antihemor-
rhagics, antianemic preparations, as well as antineoplastic and
immunomodulating agents.
In addition to a higher expenditure, most of the important bi-
ologics (in terms of sales) have experienced a very high growth
rate. Table 4 lists 20 leading biologics in terms of high growth rates
etween the effective launch year and 2006. For example, for the
nsulin aspart, which was included in the NHI formulary in 2003,
he mean annual growth rate of spending between 2003 and 2006
asmore than 4000%. Other products with amean annual growth
ate exceeding 100% include peginterferon-alfa-2a, insulin glargin,
otulinum toxin type a, etanercept, and gamma-fix. Among the 20
iologics listed in Table 3, 15 biologics are also listed in Table 4,
suggesting that most biologics with larger market size also expe-
rienced a higher growth rate in terms of their sales. Together,
Tables 3 and 4 suggest that spending on biologics in Taiwan is
ighly targeted toward about 20 products with higher annual ex-
Table 3 – The concentration index in terms of spending on
ATC code Name of ingredients Effective launch
year in NHI
formulary
B03XA01 Erythropoietin 1997
B02BD02 Factor VIII 1998
B05AA01 Albumin 1995
H01AC01 Somatotropin human
(growth hormone)
1996
L04AA11 Etanercept 2003
L03AA02 Filgrastin 1995
A10AB05 Insulin aspart 2003
L01XC02 Rituximab 2002
L01XC03 Trastuzumab 2002
L03AB11 Peginterferon-alfa-2a 2003
J06BB04 Immunoglobulin 1997
A16AB02 Imiglucerase 1999
L03AB10 Peginterferon-alpha-2b 2003
A10AD01 Insulin human 1997
B02BD09 Gamma-fix (nonacog alfa) 2004
A10AC01 Insulin human 1997
J06BA02 Immunoglobulin 1995
L03AA10 Lenograstim 1998
A10AE04 Insulin glargine 2004
B02BD03 Human plasma protein with
a factor VIII inhibitor
2004
Data Source: Bureau of National Health Insurance, Taipei, Taiwan; ca
Note:
1. The average exchange rate was around US$1 to NT$32.5 in 1998–2
2. Effective launch year indicates the timing that the biologics begin
the NHI formulary.
ATC, Anatomical Therapeutic Chemical classification system; NHI, nenditures and growth rates.Patient-Level Study
Costs and utilization patterns
Enbrel (etanercept) is one of the antitumor necrosis factor drugs
that have been shown to be effective in the treatment of rheuma-
toid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and
ankylosing spondylitis [9]. This drug was introduced into the NHI
formulary on March 1, 2003. During the period between 2003 and
2007, we identified 78 patients who had used Enbrel to treat their
diseases (Table 5). Because the sampling data set contains 1 mil-
lion persons, this suggests that the prevalence rate of Enbrel users
over a 5-year period is 7.8 per 100,000 population. Among the 78
patients we observed, 72% were female. The ages of these users
ranged from 25 to 77, with the mean age being 52.91. On average,
these patients received treatment using Enbrel for 2.31 years and
each received about 11 prescriptions per year. The mean cost per
prescription was NT$25,513, and the mean annual cost of drug
treatment per patient was NT$278,458. Overall, the results suggest
that the treatment cost using Enbrel is extremely high compared
with the treatment costs of common chronic diseases such as
hepatitis B and diabetes [10,11].
Following the same approach, we also conducted patient-level
analysis for Mabthera (rituximab), Herceptin (trastuzumab), and
Pegasys (peginterferon-alfa-2A). The utilization patterns of these
three biologics are similar to that of Enbrel. On the basis of our
analysis of Table 5, we conclude that the utilization of these four
biologics was concentrated among a smaller number of patients
and that the annual cost of treatment per patient was high, rang-
ogics in 2006.
Annual sales
(in million
NT$)
Share of total
NHI spending
on biologics
(%)
Cumulative percentage
of NHI spending on
biologics (%)
1875 23.69 23.69
1168 14.76 38.45
708 8.95 47.40
431 5.45 52.85
385 4.87 57.71
332 4.20 61.91
316 3.99 65.89
284 3.58 69.48
265 3.35 72.83
245 3.10 75.93
197 2.49 78.42
187 2.36 80.78
160 2.02 82.81
133 1.69 84.49
131 1.66 86.15
121 1.52 87.67
118 1.49 89.16
113 1.43 90.59
106 1.34 91.93
80 1.01 92.94
ted by authors.
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S39V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2user was between 6.5 and 37.2 per 100,000 population, and the
associated costs were inversely related to the prevalence rate of
drug users. A plausible explanation for this result is that the public
payer tends to impose a stronger restriction on the reimburse-
ment guideline if the treatment cost per patient is higher. Thus,
high-cost biologics are associated with a lower number of users.
Pattern of technology diffusion
Figures 2 and 3 analyze the pattern of technology diffusion by
examining the market shares of four individual biologics across
providers. In Taiwan, the regulatory agency classifies hospitals
into three accreditation levels: 1) medical center, 2) metropolitan
hospital, and 3) community hospital. The accreditation level is
positively associatedwith the size of the hospitals. In addition, the
Table 4 – Mean annual growth rate of important biologics i
ATC code Name of ingredients Effective launch
in NHI formul
A10AB05 Insulin aspart 2003
L03AB11 Peginterferon-alfa-2a 2003
A10AE04 Insulin glargine 2004
M03AX01 Botulinum toxin type a 1999
L04AA11 Etanercept 2003
B02BD09 Gamma-fix (nonacog alfa) 2001
J06BB04 Immunoglobulin 1997
L03AB10 Peginterferon-alpha-2b 2003
L03AB08 Interferon beta-1b 1998
B02BD03 Human plasma protein with
a factor VIII inhibitor
2004
L01XC02 Rituximab 2002
L03AC01 Aldesleukin 2001
L01XC03 Trastuzumab 2002
A16AB02 Imiglucerase 1999
L03AA10 Lenograstim 1998
A10AD01 Insulin human 1997
J06BB09 Immunoglobulin 1995
L04AA04 Immunoglobulin 1995
B02BD02 Factor VIII 1998
H01AC01 Somatotropin human
(growth hormone)
1996
Data Source: Bureau of National Health Insurance, Taipei, Taiwan; ca
Note:
1. The average exchange rate was around US$1 to NT$32.5 in 1998–2
2. Effective launch year indicates the timing that the biologics begin
the NHI formulary.
ATC, Anatomical Therapeutic Chemical classification system; NHI, n
Table 5 – The mean costs and utilization patterns of four s
Variable Enbrel
Number of users 78
Characteristics of users
Gender (percentage of female users) 72%
Age 52.91
Mean costs and utilization patterns
Length of treatment (y)* 2.31
Annual number of prescriptions per patient 10.94
Cost per prescription (NT$) 25,513
Annual cost of treatment per patient (NT$) 278,458
Data Source: 2005 Longitudinal Health Insurance Database, calculate
* We count the length of treatment as 1 year if the duration of the treatmdelivery of health-care services is dominated by the private sector,
which accounts for about 70% of health-care services.
The results reported in Figure 2 indicate that the likelihood of
adopting these high-cost biologics is positively correlatedwith the
size of the hospitals. With a few exceptions in the case of Pegasys,
themajority of the biologic treatments are provided by larger hos-
pitals, such as medical centers and metropolitan hospitals. In
most cases, medical centers always act as a leader in the adoption
of new biologics. Medical centers account for more than half the
market for biologics whenwe combine the four biologics together.
This suggests that physicians in larger hospitals were more likely
to prescribe new biologics as compared with their counterparts
practicing in clinics and smaller hospitals. This result is consistent
with the finding in the adoption of new antidiabetic drugs [12].
iwan.
Sales in
2006 (in million
NT$)
Mean annual growth rate in sales
between effective launch year
and 2006 (%)
316 4007.08
245 234.74
106 225.33
50 203.64
385 196.15
131 131.72
197 87.64
160 86.56
21 71.05
80 70.71
284 69.89
58 54.08
265 38.61
187 18.29
113 15.58
133 13.96
42 10.66
32 10.59
1168 10.09
431 9.22
ted by authors.
used in Taiwan’s hospitals after the biologics have been included in
al health insurance.
ed biologics.
Mabthera Herceptin Pegasys
75 65 372
52% 100% 40%
63.48 53.79 50.63
1.11 1.45 1.21
7.00 5.97 7.20
58,431 73,736 13,583
236,243 407,843 100,993
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S40 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2Figure 3 shows that the ownership forms of medical provid-
ers matter in the utilization pattern of biologics. When we com-
bine these four biologics together, the results reveal a clear pat-
tern in that the public hospitals account for a larger market
share at the entry of new technology, while the private hospitals
increased the ratio of their share of the biologics market to their
share of the market for general health care as treatment using
new biologics became more mature.
The burden of disease
In Table 6, we provide information on the burden of the disease
treated with biologics. We measured the burden of the disease by
the following four indicators: 1) total health expenditure, 2) total
drug expenditure, 3) the share of total health expenditure spent on
drugs, and 4) Charlson’s comorbidity index [13].
Because the majority of users of Enbrel were patients with
heumatoid arthritis, we focus our discussion on these patients
International Classification of Disease, 9th Revision, ClinicalMod-
fication [ICD-9-CM] 714.0). On the basis of the 2005 LHID, we iden-
ified 15,697 patients with rheumatoid arthritis during the period
003 to 2007. Among them, 78 patients had used Enbrel (users) and
he rest of them had never used Enbrel (nonusers). The results
how that themean annual total expenditure for the biologics user
as NT$771,140, which was about twice as large as the total ex-
enditure of the nonuser. Drug cost, which includes that for Enbrel
nd all other drugs, accounted for about half of the total health
xpenditure for the biologics user. By contrast, this figurewas only
bout 14% for nonusers of biologics. Charlson’s comorbidity index
as 1.73 for the user and 1.68 for the nonuser. The major indica-
ion of Mabthera is non-Hodgkin’s lymphoma, and thus the anal-
sis of the prevalence and the burden of disease for Mabthera is
ocused on non-Hodgkin’s lymphoma (ICD-9-CM 200 and 202). On
he basis of 2005 LHID, we identified 635 patients with non-Hodg-
in’s lymphoma during the period 2003 to 2007. Among them, 75
atients had previously used Mabthera (users) and the rest of
hem had never used Mabthera (nonusers). The results show that
he mean annual total expenditure for the biologics user was
T$4,513,605, which was about three times as high as the total
xpenditure for the nonuser. Drug cost, which includes that for
abthera and all other drugs, accounted for about half of the total
ealth expenditure for the biologics user. By contrast, this figure
as only about one-third for the nonuser of biologics. Charlson’s
omorbidity index was 7.94 for the user and 7.04 for the nonuser.
The fourth column of Table 6 reports the prevalence and bur-
en of the malignant neoplasm of the female breast (ICD-9-CM
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Fig. 2 – The market share (in terms of NHI spending) of four
selected biologics based on the accreditation level of
hospitals. From 2005 Longitudinal Health Insurance
Database, calculated by authors. NHI, national health
insurance.74), themajor indication for Herceptin. On the basis of 2005 LHID,e identified 3704 patients with malignant neoplasm of the fe-
ale breast during the period 2003 to 2007. Among them, 65 pa-
ients had used Herceptin (users) and the rest of them had never
sedHerceptin (nonusers). The results show that themean annual
otal expenditure for the biologics user was NT$3,016,309, which
as more than four times as large as the total expenditure for the
onuser. Drug cost, which includes that for Herceptin and all other
rugs, accounted for about 57% of the total health expenditure for
he biologics user. By contrast, this figure was only about 21% for
he nonuser of biologics. Charlson’s comorbidity index was 15.74
or the user and 4.81 for the nonuser.
The last column of Table 6 reports the prevalence and burden
f chronic liver disease, cirrhosis, and hepatitis B and C (ICD-9-CM
71, 070.3, 070.5), which are the major indications for Pegasys [14].
n the basis of 2005 LHID, we identified 127,484 patients with
hronic liver disease, cirrhosis, and hepatitis B and C during the
eriod 2003 to 2007. Among them, 372 patients had used Pegasys
users) and the rest of them had never used Pegasys (nonusers).
he results show that the mean annual total expenditure for the
iologics user was NT$617,102, which was more than twice as
arge as the total expenditure for the nonuser. Drug cost, which
ncludes that for Pegasys and all other drugs, accounted for about
6% of the total health expenditure for the biologics user. By con-
rast, this figure was only about 16% for the nonuser of biologics.
harlson’s comorbidity indexwas 1.86 for the user and 0.97 for the
onuser.
Overall, these results provide a consistent pattern showing
hat the burden of the diseases for patients treated with biologics
as significantly higher than that for patients without treatment
nvolving biologics. This result suggests that biologics were more
ikely to be used in patients with a higher severity of diseases and
igher comorbidities.
Discussion
This article explored several issues surrounding the use of biolog-
ics in Taiwan, including the accessibility, health-care costs, and
utilization patterns. On the dimension of accessibility, we found
that the probability of launching a new and important biologic
product in Taiwanwas 0.7, that is, for every 10 important biologics
prevailing in the global market, only 7 will be introduced into the
NHI formulary in Taiwan. This suggests that the public health
insurance in Taiwan is not “affordable” for every new technology
available in the global market: only about two-third of new biolog-
ics are available through public health insurance and the remain-
ing one-third are “unavailable.” To what extent the unavailable
new technologies in Taiwan’s public health insurance program
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Fig. 3 – The market share (in terms of NHI spending) of four
selected biologics based on the ownership form of
hospitals. From 2005 Longitudinal Health Insurance
Database, calculated by authors. NHI, national health
insurance.
S41V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2are due to cost concerns is an important avenue for future re-
search.
With regard to health-care costs, we found that the growth rate
of spending on biologics significantly exceeded the growth rate of
spending on all prescription drugs. As a result, the share of bio-
logic spending in NHI pharmaceutical expenditure increased rap-
idly, from 3.7% in 1998 to 6.8% in 2006. However, this share was
less than the corresponding share observed in the United States
and other European countries. This suggests that policymakers in
Taiwan face a trade-off between increasing access to new biolog-
ics and controlling health-care costs.
With regard to the utilization patterns of biologics, our major
findings are summarized as follows. First, although there are 68
biologics included in the NHI formulary, the spending on these
biologics was highly concentrated. The concentration index
among the 20 leading biologics was more than 90% of the total
biologic spending.
Second, we found that the utilization of biologics was concen-
trated among a smaller number of patients and that the annual
cost of treatment per patient was high. In our study on four indi-
vidual biologics, the annual cost of treatment per patient ranged
from NT$100,000 to NT$400,000. The prevalence rate of the user
ranged from 6.5 to 37.2 per 100,000 population. We also found that
the treatment costs were inversely related to the prevalence rate
of drug users. That is, the higher the mean treatment cost per
patient, the smaller the number of users will be.
Third, we found that the size and ownership forms of med-
ical providers matter in the adoption of new biologics in Tai-
wan. Overall, we found that public hospitals and larger hospi-
tals, such as medical centers, were the leaders in technology
adoption, while other hospitals were the followers. We found
that physicians in larger hospitals as well as those in public
hospitals were more likely to prescribe new biologics to their
patients as compared with their counterparts practicing in
smaller and private hospitals, which might result from the fact
that some new biologics must be prescribed by a number of
specialists and large hospitals.
Finally, we found that the burden of the diseases was signifi-
cantly higher for the user of the biologics than for the nonuser.
This suggests that physicians aremore likely to prescribe biologics
Table 6 – The prevalence and the burden of disease for fou
Items Rheumatoid
arthritis (Enbrel)
Non-Hod
lymphoma (M
User of biologics
Number of patients 78 7
Annual total expenditure (NT$) 771,140 4,513,60
Annual drug expenditure (NT$) 383,670 2,304,51
Percentage of drug spending in
total expenditure
49.75 5
CCI* 1.73
Nonuser of biologics
Number of patients 15,619 56
Annual total expenditure (NT$) 368,712 1,675,58
Annual drug expenditure (NT$) 52,400 558,43
Percentage of drug spending in
total expenditure
14.21 3
CCI* 1.68
All
Number of patients 15,697 63
Percentage of biologics user 0.49 1
Data Source: 2005 Longitudinal Health Insurance Database, calculate
* CCI indicates Charlson’s comorbidity index [13].to patients with more severe diseases and higher comorbidities,indicating that the clinical factor also plays an important role in
guiding the physicians’ decisions in biologic treatment.
There are two limitations to our study. First, the insurance
claims data do not contain any information on clinical indicators.
The lack of such data restricted us from further evaluating
whether the use of biologics in Taiwan was appropriate. That is,
the lack of clinical data limited us from answering the question as
to whether biologics were “underused” or “overused” in Taiwan.
Second, the insurance claims data do not contain information on
the health outcome, either. This, in turn, further restricted us from
comparing the health-care costs of biologics with their potential
benefits.
Conclusion
In this article, we first investigated the access and cost issues in
the use of biologics in Taiwan bymeans of amarket-level analysis
that analyzed the aggregate expenditure of important biologics.
We then performed a patient-level analysis to analyze the utiliza-
tion patterns of selected biologics. On the basis of these findings,
we conclude that spending on biologics is highly concentrated in a
small number of biologics and that the utilization of these biolog-
ics is targeted at a small number of patients. As a result, the use of
biologics is very costly. In addition, we find that the determinants
of the use of biologics include not only clinical factors, such as
disease severity, but also economic factors, such as the size and
ownership forms of hospitals.
Our results have two important policy implications. First, given
the evidence that the use of biologics is costly, it is important to
compare the gains from biologics treatment in terms of the health
outcome with the increase in health expenditure to achieve an
efficient allocation of health-care resources. It is not a wise strat-
egy to restrict the introduction of new biologics into the NHI for-
mulary for the purpose of saving money, but neither is writing a
blank check for all new biologics. Thus, careful, but expeditious,
analysis of the costs versus benefits of individual new biologics
before their introduction represents a promising approach for
boosting the value of public spending.
Second, given the evidence that the probability of receiving
ected biologics.
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S42 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 3 5 – S 4 2hospitals, our findings imply that access to costly biologics is not
uniform among patients in a country with universal coverage for
prescription drugs. Many nonclinical factors such as physicians’
financial incentives may also play an important role in the physi-
cians’ prescription decisions, which, in turn, may create an access
barrier in the use of new biologics in Taiwan, even though the new
biologics are included in the NHI formulary.
Acknowledgment
We acknowledge with thanks the extensive data support from
C.W. Kuo.
Source of financial support: This researchwas supported by the
National Science Council in Taiwan and Worldwide Health Eco-
nomics Johnson and Johnson Pharmaceutical Services, New Jer-
sey. Any opinions expressed herein are those of authors and do
not necessarily reflect the views and judgments of the sponsors or
the institutes with whom the authors are affiliated.
R E F E R E N C E S
[1] Baumann A. Early development of therapeutic
biologics—pharmacokinetics. Curr Drug Metab 2006;7:15–21.
[2] Lacanà E, Amur S, Mummanneni P, et al. The emerging role of
pharmacogenomics in biologics. Clin Pharmacol Ther 2007;82:466–71.[3] Trusheim M, Aitken ML, Berndt ER. Characterizing markets for
biopharmaceutical innovations: do biologics differ from smallmolecules? Forum Health Econ Policy 2010;13(1): Article 4. Available
from: http://www.bepress.com/fhep/13/1/4. [Accessed November 30,
2011].
[4] Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related
regulatory actions for biologicals approved in the United States and
the European Union. JAMA 2008;300:1887–96.
[5] Simon F. Market access for biopharmaceuticals: new challenges.
Health Aff (Millwood) 2006;25:1363–9.
[6] Hsieh CR. Pharmaceutical policy in Taiwan. In: Eggleston K., ed.,
Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific.
Baltimore, MD: Brookings Institution Press, 2009.
[7] Danzon PM, Wang YR, Wang L. The impact of price regulation on the
launch delay of new drugs: evidence from 25 markets in the 1990s.
Health Econ 2005;14:269–92.
[8] Danzon PM, Furukawa MF. Prices and availability of
biopharmaceuticals: an international comparison. Health Aff
(Millwood) 2006;25:1353–62.
[9] Kay LJ, Griffiths ID. UK consultant rheumatologists’ access to biological
agents and views on the BSR biologics register. Rheumatology 2006;45:
1376–9.
10] Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in
Taiwan. J Clin Gastroenterol 2004;38(Suppl.):S148–52.
11] Liu YM, Hsieh CH. New drugs and the growth of health expenditures:
empirical evidence from diabetic patients in Taiwan. Health Econ
2011;DOI: 10.1002/hec.1724.
12] Liu YM, Kao Yang YH, Hsieh CR. The determinants of the adoption of
pharmaceutical innovation: evidence from Taiwan. Soc Sci Med 2011;
72:919–27.
13] Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies:
development and validation. J Chronic Dis 1987;40:373–83.
14] Sullivan SD, Veenstra DL, Chen PJ, et al. Cost-effectiveness of
peginterferon alfa-2a compared to lamivudine treatment in patients
with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J
Gastroenterol Hepatol 2007;22:1494–9.
